Various authors have considered at some length the natural functions (if any) of antibiotics. Under certain circumstances (always presupposing that a given antibiotic producer is insensitive to its product) production of an antibiotic might remove competitors from an ecological niche; however, it has also been argued that the advantages to be gained from secondary metabolism may be more obscure (4, 11) . Thus (4), secondary metabolism might allow a cell to maintain essential enzymes and entire uptake or synthetic systems in working order after the cessation of primary metabolism (i.e., cell growth), perhaps allowing a more rapid resumption of growth if, and when, conditions became more favorable. Alternatively (11) one can consider the advantages to a cell (but not necessarily at the expense of its neighbors) of excreting secondary metabolites of no use to itself. These could arise from the action of enzymes upon normal metabolic intermediates after their accumulation in abnormal amounts after inhibition of growth. According to this hypothesis, biological activity of excreted secondary metabolites might be accidental, but not so surprising, since many of them would resemble normal metabolic intermediates and might be potent antimetabolites. Both of these hypotheses (others are not excluded) leave open the question of whether antibiotic producers should be expected to be susceptible or resistant to their products.
We have initiated a program of investigation into the effects of ribosome inhibitors upon the organisms which produce them. Surprisingly, although it was shown some time ago (10) that a streptomycin-producing Streptomyces was tolerant of streptomycin, there appear to have been few detailed examinations of the properties of the ribosomes of organisms which produce inhibitors of protein synthesis. There are, however, notable exceptions. Extracts of a Streptomyces which produces chloramphenicol, synthesizing polyphenylalanine in response to added poluridylic acid, were susceptible to inhibition by chloramphenicol and the ribosomes bound the drug indistinguishably from those of Escherichia coli (6) . Conversely, protein synthesis in extracts of a Streptomyces which produces tetracycline was resistant to tetracycline, although the drug was still able to bind to the ribosomes (7).
Here we report that the streptomycete which makes thiostrepton possesses thiostreptonresistant ribosomes which bind the drug very poorly. In contrast, the bacteria which produce micrococcin possess ribosomes which are susceptible to micrococcin in vitro, although whole cells of these organisms are micrococcin resistant.
MATERIALS AND METHODS
Growth of Streptomyces azureus and production of crude [35Sjthiostrepton. The organism was grown in fermentor medium which contained per liter: tryptone, 10 g; malt extract, 15 g; glucose, 20 g; yeast extract, 3 g; and maltose, 20 g. Fermentor agar as used for plates in experiments described in Table 1 was made by adding agar (1.5% wt/vol, final concentration) to the above medium. The organism was grown from spores in a starter culture (50 ml) for 36 h and this was then used to inoculate 500 ml of fermentor medium (at zero time 
RESULTS
A group of antibiotics comprising thiostrepton, siomycin, micrococcin (and the identical compound, micrococcin P), sporangiomycin, and thiopeptin have been shown to possess closely related modes of action upon bacterial protein synthesis in vivo and in vitro (E. Cundliffe and P. Dixon, manuscript in preparation).
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We also determined that siomycin, thiopeptin, sporangiomycin, and, to a much lesser extent, micrococcin inhibit the binding of [35S]thiostrepton to bacterial ribosomes, indicating that the binding sites for these compounds are either identical or are intimately associated on the ribosome. Accordingly, we examined the susceptibilities towards these various antibiotics of S. azureus which produces thiostrepton, Su's Micrococcus (5, 8) which produces micrococcin, and B. pumilis which produces micrococcin P (3). The results are given in Table 1 . Although susceptible to a range of compounds which inactivate 70S ribosomes, S. azureus was resistant to the entire thiostrepton group, whereas S. coelicolor (included as a control to establish the fact that streptomycetes in general are not thiostrepton resistant) was susceptible to each drug employed. Cross resistance to the entire thiostrepton group was also observed in two spontaneously arising mutants of Bacillus megaterium KM selected for resistance to thiostrepton (P. D. Dixon, unpublished data), whereas the wild type was susceptible to these drugs. In contrast, Su's Micrococcus and B. pumilis were resistant only to the antibiotic which they produce and were susceptible to other members of the thiostrepton group.
To examine in vitro the ribosomes of these various organisms, we studied in some detail one of the partial reactions of protein synthesis. The cycle of events which accompanies the addition of each amino acid to a nascent peptide chain includes the formation of a complex between the ribosome, the protein EF G, and GTP, as a consequence of which GTP is cleaved to guanosine diphosphate and inorganic phosphate. The antibiotic fusidic acid allows the GTPase event to occur but stabilizes the resultant ribosome-EF G-guanosine diphosphate complex which can then be recovered on a membrane filter (Millipore Corp.) (2) . The formation of such complexes (from either GTP or guanosine diphosphate) was specifically inhibited by the thiostrepton group of antibiotics (no other antibiotics have yet been shown to inhibit this reaction) and we took advantage of this fact to examine the susceptibilities of the ribosomes of S. azureus and Su's Micrococcus towards this group of antibiotics. Results obtained with ribosomes of B. pumilis were similar to those of the Micrococcus and are not given here. One further point which must be emphasized is that the lack of purified EF G from organisms other than E. coli necessitated the use of heterologous systems involving this material and ribosomes from other organisms. Tables 2 and 3. As shown in Table 2 , ribosomes from S. azureus continued to support the formation of ribosome-EF G-guanine nucleotide complexes after exposure to antibiotics of the thiostrepton group, whereas similar systems employing ribosomes from S. coelicolor or B. megaterium KM were markedly inhibited. In contrast (Table 3) , ribosomes from Su's Micrococcus were more susceptible to micrococcin than were ribosomes from B. megaterium KM or E. coli and were, as expected from Table 1 Having ascertained that ribosomes of S. azureus were resistant to inhibition by thiostrepton, we sought to determine whether this resistance originated from an inability of the ribosomes to bind the drug or from a lack of inhibitory response to bound drug. As shown in Fig. 2 Whether the phenomenon of intrinsic resistance of a streptomycete to its own toxic product is part of a general pattern remains to be determined. In particular, it will be of interest to study the organisms which produce aminoglycoside antibiotics and which may have available an enzymic mechanism of resistance (1) . Whether such organisms would need to possess drug-resistant ribosomes remains to be seen.
While this work was in its final stages of completion we learned (9) that Streptomyces erythreus (an erythromycin producer) possesses ribosomes which are not inhibited by erythrornycin nor do they bind the drug; results analogous to those which we report here.
